Abbisko Out-Licenses Rights to Non-Oncology Indications for CSF-1R Inhibitor
July 06, 2021 at 07:12 AM EDT
Abbisko Therapeutics of Shanghai out-licensed greater China rights for ABSK021 to Sperogenix ( Shanghai ) MedTech. Sperogenix will develop the candidate only for non-oncology rare neurological diseases indications in China , with amyotrophic lateral sclerosis (ALS) as the first target. Abbisko will receive upfront and milestone payments as well as royalties on annual net sales from Sperogenix, while it continues to hold rights to the candidate for oncology diseases. ABSK021 is an oral, selective colony-stimulating factor 1 receptor (CSF-1R) antagonist. More details.... Share this with colleagues: // //